Levetiracetam

Levetiracetam is an anticonvulsant used mainly as adjunctive therapy when seizures are not adequately controlled with other antiseizure medicines. Its approved seizure uses include partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures. It may be used in patients of all ages, including infants from 1 month of age, when the prescribed indication and formulation are appropriate. The drug binds to synaptic vesicle protein SV2A. This changes neurotransmitter release at nerve terminals, reducing neuronal hyper-excitability and limiting seizure propagation. The practical nursing meaning is that levetiracetam helps prevent recurrent seizure activity; it does not make an oral dose an appropriate response while a patient is actively convulsing. Most levetiracetam is cleared by the kidneys with minimal cytochrome P450 involvement. That explains two important patterns: - It has fewer metabolic drug interactions than many older antiseizure medicines. - Reduced renal clearance can increase exposure, so kidney function directly affects dosing. “Few interactions” does not mean “no interactions.” Enzyme inducers such as carbamazepine, phenytoin, and phenobarbital may reduce levetiracetam concentrations. Medicines that also depend on renal clearance, including aminoglycosides, warrant closer attention...